Peroxisomal GPP Pathway Compartmentalization in Yeast
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing monoterpenoids, cannabinoids, iridoids, and prenylated aromatic compounds in yeast face challenges due to the competition between engineered pathways and native metabolism, leading to low yields and metabolic burdens, particularly at the GPP branch-point where GPP is prioritized for sterol synthesis over these compounds.
Innovation Solution
Localization of GPP synthase and the first step enzyme of the non-prioritized pathway, such as monoterpene synthase, to the peroxisomes in yeast cells, diverting GPP towards the production of monoterpenoids, cannabinoids, and prenylated aromatic compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If GPP synthase and monoterpene synthase are localized to the peroxisomes, then production of monoterpenoids is enhanced 32-fold, but cellular organization and metabolism are altered
Solution Approach 1:
The patent divides the metabolic pathway into spatially separated segments by localizing GPP synthase and monoterpene synthase to peroxisomes, while leaving other pathway enzymes in the cytosol. This segmentation isolates the monoterpene production pathway from competing native metabolism, achieving 32-fold enhanced productivity while maintaining manageable cellular organization through targeted compartmentalization rather than complete pathway relocation.
2Quantity of substance
If GPP is diverted to monoterpene production, then yield of monoterpenoids increases, but sterol synthesis is compromised
Solution Approach 1:
The patent extracts the GPP production and monoterpene synthesis steps from the cytosolic compartment where sterol synthesis occurs, relocating them to peroxisomes. This extraction creates a separate metabolic zone that produces GPP for monoterpene synthesis without depleting the cytosolic GPP pool needed for sterol biosynthesis, thereby increasing monoterpene yield while preserving sterol synthesis reliability.
Solution Approach 2:
The peroxisome acts as an intermediary compartment that receives GPP from cytosolic GPP synthase and converts it to monoterpenes via monoterpene synthase. This intermediary structure allows GPP to be diverted to monoterpene production without directly competing with sterol synthesis in the cytosol, as the peroxisome serves as a buffer zone that processes GPP separately from the native sterol pathway.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly enhances the production of these compounds by 32-fold for monoterpenes and improves the yield of precursors for cannabinoids and iridoids, addressing the metabolic constraints and achieving industrially viable titers.
Implementation Method 1
Localization of GPP synthase and the first step enzyme of the non-prioritized pathway, such as monoterpene synthase, to the peroxisomes in yeast cells, diverting GPP towards the production of monoterpenoids, cannabinoids, and prenymted aromatic compounds.
Data Source
AI summary
Disclosed is yeast cells having peroxisomally localized GPP synthase and a peroxisomally localized enzyme that converts GPP into a monoterpenoids, cannabinoids, monoterpene indole alkaloids and prenylated aromatic compounds; or a precursor therefore, which yeast cells are capable of producing improved amounts of monoterpenoids, cannabinoids, monoterpene indole alkaloids and prenylated aromatic compounds, compared with the same yeast cells where the GPP synthase and the enzyme that converts GPP are located in the cytoplasm. Further disclosed is the use of the yeast cell for producing monoterpenoids, cannabinoids, monoterpene indole alkaloids and prenylated aromatic compounds.